Alnylam Pharmaceuticalsvs.United Therapeutics
ALNY vs UTHR · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Alnylam Pharmaceuticals is about 1.3× larger than United Therapeutics by market cap; United Therapeutics trades at the lower P/E (17.4 vs 37.2); year to date, United Therapeutics leads (+9.3% vs −43.5%).
Side by side
| ALNY | UTHR | |
|---|---|---|
| Market cap | $30B | $22.9B |
| Price | $232.68 | $549.16 |
| Today | +3.6% | +3.1% |
| Return YTD | −43.5% | +9.3% |
| Return 1Y | −50.2% | +18.7% |
| Since June 26, 2026 | −20.1% | +1.2% |
| P/E | 37.2 | 17.4 |
| P/S | 6.3 | 7.2 |
| P/B | 22.2 | 3.6 |
Data as of 2026-10-09 · updates daily after U.S. close
Since June 26, 2026: the change in the closing price, from the daily closes Sectivia records itself since that date.
The two companies
Alnylam PharmaceuticalsALNY
Turns RNA interference into drugs, mostly for rare and cardiovascular disease.
Full ALNY profile →United TherapeuticsUTHR
Pulmonary hypertension accounts for the marketed drugs, Tyvaso, Remodulin and Orenitram among them. A separate programme works on organs for transplant, including xenotransplantation.
Full UTHR profile →More ALNY & UTHR comparisons
Other head-to-heads in the Biotech & innovation segment.